Camurus

Board/Management Information • Oct 28, 2016

Camurus AB Ideon Science Park SE-223 70 Lund, Sweden www.camurus.com Phone: +46 46 286 57 30

Press release

Nomination Committee appointed in respect of AGM 2017 in Camurus

Lund - 28 October 2016 - According to the instruction for Nomination Committee in Camurus AB adopted at the annual general meeting held on 3 May 2016, the Nomination Committee for the annual general meeting shall be composed of representatives of the three largest shareholders in terms of voting rights as of 31 August, along with the Chairman of the Board of Directors. The composition of the Nomination Committee has now been established, and Camurus today announced that the Nomination Committee in respect of the AGM 2017 consists of the following persons who together represent approximately 65 percent of the number of shares and votes in the company based on the last known shareholder information.

• Martin Jonsson, representing Sandberg Development AB
• Jan Andersson, representing Swedbank Robur Fonder
• Pär Josefsson, representing Fredrik Tiberg, and
• Per Olof Wallström, Chairman of the Board

The Nomination Committee's proposals will be presented in the Notice to the Annual General Meeting 2017 and on Camurus' web site, www.camurus.com.

Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee at the company's address. Proposals shall be submitted in due time before the Annual General Meeting, but not later than 31 January 2017, to ensure that the proposals can be considered by the Nomination Committee.

About Camurus

Camurus is a Swedish research-based pharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drua products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus' clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker "CAMX". For more information, visit www.camurus.com.

For more information

Per Olof Wallström, Chairman of the Board Tel. +46 709 42 95 20 p.o.wallstrom@telia.com

The information was submitted for publication at 07.00 a.m. CET on 28 October 2016.